



Jane Quigley

Vice President, Medical Informatics

Jane Quigley leverages patient- and physician-level data to aid in disease modelling, real-world evidence, health outcomes research, and therapeutic forecasting. She works with PRA clients from pre-clinical development through post marketing safety and surveillance. Her work with de-identified patient-level data has been presented globally at the European Society for Medical Oncology/European Cancer Congress, American Society for Clinical Oncology, American Society of Hematology, and the San Antonio Breast Cancer Symposium. She is also the author of over 60 manuscripts and abstracts and has been published in Journal of the National Comprehensive Cancer Network and The Journal of Oncology. Prior to joining PRA, Jane Quigley was a Senior Principal at IMS Health. She was the lead consultant for Global Oncology, partnering with clients across their oncology portfolios including pricing, market access, and regulatory requests. Prior to IMS Health, Jane Quigley was Vice President at IntrinsicQ LLC. While at IntrinsicQ, she expanded their clinical consulting capabilities and worked extensively with the financial sector, including Goldman Sachs, Rodman & Renshaw, and Sanford Bernstein. Jane Quigley was the Clinical Nurse Specialist for the Division of Hematology/Oncology at Georgetown-The Lombardi Cancer Center, Director of Bone Marrow Transplantation and PBSCT. She is a member of ASCO and ONS and has a BSN from Georgetown University. Ms Quigley has over 23 years of clinical hematology and oncology experience.

About PRA Health Sciences

PRA Health Sciences (PRA) is one of the world's leading global contract research organizations, or CROs, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. Side-by-side with clients, PRA strives to move drug discovery forward to help develop life-saving and life-improving drugs.

PRA has therapeutic expertise in areas that are among the largest in pharmaceutical development, including oncology/hematology, CNS (neurology/psychiatry), cardio-metabolic diseases, inflammation/immunology, infectious diseases, rare diseases, respiratory, and biosimilars.

Since 2000, PRA has performed more than 3,100 clinical trials worldwide and has worked on more than 100 marketed drugs across several therapeutic areas. With more than 11,000 employees worldwide, PRA's global clinical development platform spans 70+ offices across North America, Latin America, Europe, South Africa, the Middle East, Asia, and Australia.